What is Optimed Research?
Optimed Research, Ltd. is a national network specializing in Allergy, Immunology, Ophthalmology, and Neurology/CNS clinical research, founded over 25 years ago by Dr. Donald McNeil. The firm is adept at managing Phase II-IV studies, leveraging advanced cloud-based technology and real-time data capture to streamline trial processes. By facilitating patient and physician participation in clinical trials, Optimed Research plays a crucial role in accelerating the drug development pipeline and improving patient access to novel treatments. Their commitment to quality ensures efficient trial management and contributes to the advancement of medical therapies.
How much funding has Optimed Research raised?
Optimed Research has raised a total of $304K across 2 funding rounds:
Debt
$150K
Debt
$154K
Debt (2020): $150K with participation from PPP
Debt (2021): $154K led by PPP
Key Investors in Optimed Research
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Optimed Research?
With substantial late-stage funding, Optimed Research is poised for significant scaling and enhancement of its operational capabilities. This strategic investment will likely fuel the expansion of its research network, the adoption of cutting-edge technologies for data analytics, and the broadening of its therapeutic area focus. The company's emphasis on efficient trial management and patient access suggests a strategic direction aimed at solidifying its role as a key facilitator in bringing new treatments to market, potentially through strategic partnerships or acquisitions to further its reach and impact in the pharmaceutical and biotechnology sectors.
See full Optimed Research company page
